Search

Your search keyword '"Brais, Lauren"' showing total 188 results

Search Constraints

Start Over You searched for: Author "Brais, Lauren" Remove constraint Author: "Brais, Lauren"
188 results on '"Brais, Lauren"'

Search Results

152. A blood-based metabolomic signature predictive of risk for pancreatic cancer

154. Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus

157. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors

158. Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors

159. Abstract 2199: Associations of genetic polymorphisms in VEGFR1 with progression-free and overall survival in patients with neuroendocrine tumors treated with the VEGFA inhibitor bevacizumab.

160. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database

163. Diagnostic TR-FRET assays for detection of antibodies in patient samples

165. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors

167. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.

168. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer

169. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer

170. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21

171. Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.

172. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.

173. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21

174. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer

175. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.

176. Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers.

177. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.

178. Experience and Needs of Patients With Young-Onset Colorectal Cancer and Their Caregivers: A Qualitative Study.

179. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.

180. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.

181. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer.

182. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories.

183. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity.

184. Utility of Normalized Body Composition Areas, Derived From Outpatient Abdominal CT Using a Fully Automated Deep Learning Method, for Predicting Subsequent Cardiovascular Events.

185. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.

186. Spatially organized multicellular immune hubs in human colorectal cancer.

187. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer.

188. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer.

Catalog

Books, media, physical & digital resources